Your browser doesn't support javascript.
loading
Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy.
Duan, Li-Juan; Wang, Qian; Zhang, Cuilian; Yang, Dong-Xiao; Zhang, Xu-Yao.
Afiliação
  • Duan LJ; Medical School, Huanghe Science and Technology College, Zhengzhou, China.
  • Wang Q; Reproductive Medicine Center, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang C; Reproductive Medicine Center, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
  • Yang DX; Medical School, Huanghe Science and Technology College, Zhengzhou, China.
  • Zhang XY; Medical School, Huanghe Science and Technology College, Zhengzhou, China.
Front Immunol ; 13: 923647, 2022.
Article em En | MEDLINE | ID: mdl-35711457
ABSTRACT
Immunotherapy has become the breakthrough strategies for treatment of cancer in recent years. The application of messenger RNA in cancer immunotherapy is gaining tremendous popularity as mRNA can function as an effective vector for the delivery of therapeutic antibodies on immune targets. The high efficacy, decreased toxicity, rapid manufacturing and safe administration of mRNA vaccines have great advantages over conventional vaccines. The unprecedent success of mRNA vaccines against infection has proved its effectiveness. However, the instability and inefficient delivery of mRNA has cast a shadow on the wide application of this approach. In the past decades, modifications on mRNA structure and delivery methods have been made to solve these questions. This review summarizes recent advancements of mRNA vaccines in cancer immunotherapy and the existing challenges for its clinical application, providing insights on the future optimization of mRNA vaccines for the successful treatment of cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China